March 18 (Reuters) - Pfizer ( PFE ) will sell its remaining stake in British consumer

healthcare group Haleon ( HLN ), the companies said on Tuesday.

Pfizer ( PFE ) will sell about 662 million ordinary shares, or 7.3%, of Haleon ( HLN ), created in a merger

of GSK and Pfizer's ( PFE ) consumer healthcare businesses in 2019, and spun off in 2022.

Under the deal, the Sensodyne maker has agreed to buy back shares worth $220 million from

Pfizer ( PFE ), currently its largest shareholder.

GSK, which initially owned nearly 13% of the firm, sold its entire stake in May 2024.

Following Pfizer's ( PFE ) disposal, BlackRock Investment Management (UK) Ltd, a unit of BlackRock ( BLK )

, will become Haleon's ( HLN ) largest shareholder with over a 5% stake, according to data

compiled by LSEG.

Haleon ( HLN ) in February said its 2025 revenue and profit growth weighted to the second half of

the year.